Agonist

An agonist is a ligand that binds to a specific cell-surface or intracellular receptor, stabilizing the receptor in its active conformational state to stimulate signal transduction cascades. Agonists can be classified as full agonists (achieving 100% maximal efficacy), partial agonists, or biased agonists (selectively stimulating one intracellular signaling branch over another, such as G-protein activation versus beta-arrestin recruitment).

Therapeutic incretins are agonists at the GLP-1 and GIP receptors. Tirzepatide functions as a biased agonist at the GLP-1 receptor, favoring cAMP second-messenger production while minimizing beta-arrestin-mediated receptor internalization.

Almost every modern peptide drug is described by what it does at a receptor, and “agonist” is the word you will meet most often. Semaglutide, liraglutide and tirzepatide are all agonists: they switch on receptors the body already uses for its own hormones. Knowing that tells you the drug’s effects should look like an amplified, longer-lasting version of a natural signal, including its side effects, rather than something entirely new.

The label also helps you test marketing claims. A product sold as a “GLP-1 agonist” or a “growth hormone secretagogue” is claiming a specific receptor action. For approved drugs that action has been measured in laboratory assays and confirmed by clinical outcomes. For many research-chemical peptides the receptor claim rests on cell or animal work only, so “it’s an agonist” describes a proposed mechanism, not proof of a benefit in people.

Finally, agonists are not all equal. Full, partial and biased agonists can bind the same receptor yet produce different strengths or patterns of signalling. Tirzepatide is a published example: laboratory work found it favours one signalling branch of the GLP-1 receptor over another. Details like this are part of why two drugs aimed at the same receptor can behave differently.

“Agonist means it boosts your own hormone levels”

An agonist does not usually make the body produce more of its own hormone. It binds the receptor directly and imitates the hormone’s signal. Semaglutide, for example, activates GLP-1 receptors itself; it does not work by raising natural GLP-1. Some peptides do act indirectly by triggering release of another hormone, so the specific mechanism always needs checking.

“Same receptor, same drug”

Two agonists at one receptor can differ in potency, how fully they activate it, which internal pathways they favour, and how long they last in the body. Those differences can change both benefits and side effects. Results from one GLP-1 receptor agonist therefore cannot simply be transferred to another compound, and certainly not to an untested research peptide that claims the same target.

“Proven agonist means proven treatment”

Showing that a molecule activates a receptor in a dish is an early step. Whether that translates into a meaningful, safe effect in people depends on absorption, half-life, dosing, side effects and, above all, controlled human trials. Many compounds with convincing receptor activity never become approved medicines.

What is a GLP-1 agonist?

A GLP-1 receptor agonist is a drug that binds and activates the receptor for glucagon-like peptide-1, a gut hormone involved in insulin release, stomach emptying and appetite. Semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide (Victoza, Saxenda) are examples. They are engineered to last far longer than natural GLP-1, which the body breaks down within minutes.

What is the difference between an agonist and an antagonist?

Both bind to a receptor, but an agonist activates it and triggers a response, while an antagonist occupies it without activating it, blocking the natural signal. In the lock-and-key picture, an agonist turns the lock and an antagonist jams it. Some drugs fall in between as partial agonists, producing a weaker maximum response.

Is tirzepatide a GLP-1 agonist?

Tirzepatide is a dual agonist: it activates both the GIP receptor and the GLP-1 receptor. Laboratory research has described it as “imbalanced” (engaging the GIP receptor more strongly) and “biased” at the GLP-1 receptor, favouring cAMP signalling over beta-arrestin recruitment. It is approved as Mounjaro for type 2 diabetes and Zepbound for weight management.

What is a partial agonist?

A partial agonist binds and activates a receptor but cannot produce the full maximum response, even when every receptor is occupied. Because it takes up receptor sites, it can also blunt the effect of a full agonist present at the same time. Whether a drug is a full or partial agonist can matter for both its strength and its side effects.